Table 1.

Effects of KCNQ/M channel modulators linopirdine (10 μm), XE991 (3 μm), and retigabine (10 μm) on passive and active membrane properties of CA1 pyramidal cells

Control (n = 20) Linopirdine (n = 20) Control (n = 7) XE991 (n = 7) Control (n = 5) Retigabine (n = 5)
Resting potential (mV) −69.9 ± 3.3* −64.7 ± 4.8* −67.7 ± 3.2 −65.6 ± 3.2 −68.0 ± 2.1* −72.8 ± 3.2*
Input resistance (MΩ) 35.4 ± 11.7* 40.3 ± 16.6* 38.9 ± 11.6 44.7 ± 16.1 40.1 ± 11.3* 24.8 ± 3.1*
Spike threshold (mV) −58.9 ± 2.8 −56.9 ± 3.9 −62.5 ± 5.1 −61.8 ± 4.4 −63.5 ± 3.8 −60.2 ± 4.8
Spike rise time (msec) 0.16 ± 0.49 0.14 ± 0.3 0.15 ± 0.4 0.14 ± 0.24 0.14 ± 0.23 0.15 ± 0.25
Spike amplitude (mV) 92.0 ± 7.0 93.6 ± 6.6 96.6 ± 6.7 97.9 ± 7.5 96.6 ± 5.5 98.1 ± 3.6
Spike width (msec) 0.83 ± 0.09* 0.95 ± 0.17* 0.84 ± 0.62* 0.90 ± 0.3* 0.85 ± 0.1* 0.97 ± 0.1*
Fast AHP (msec) −60.1 ± 3.3* −57.7 ± 3.4* −61.9 ± 4.9* −60.2 ± 4.5* −62.4 ± 2.6 −59.4 ± 3.5
ADP size (mV·msec) 180.3 ± 40.1* 295.2 ± 89.9* 180.9 ± 77.8* 287.6 ± 109.8* 203.5 ± 58.2* 132.2 ± 61.3*
  • The asterisks denote significant differences between mean values in controls versus the drug-treated group (paired Student's t test; p < 0.05).